Reduced expiratory variability index (EVI) is associated with controller medication withdrawal and symptoms in wheezy children aged 1-5 years

Abstract

Background: Lung function testing is an essential part of diagnostic workup and monitoring of asthma, but young children are lacking easy, routine testing methods. However, recent discoveries show reduced tidal breathing variability measured using impedance pneumography (IP) at home during sleep as a sign of airway obstruction. In this study, we assessed (a) the discriminative capacity of expiratory variability index (EVI) between healthy controls and young children with recurrent wheeze on-and-off controller medication, (b) association between EVI and parentally perceived obstructive symptoms (need for bronchodilator) and (c) measurement success rate.

Methods: We included 68 patients (aged 1.0-5.6) and 40 healthy controls (aged 1.0-5.9 years). The patients were prescribed a three-month inhaled corticosteroid (ICS) treatment due to recurrent obstructive bronchitis. We measured EVI using IP at home at the end of the treatment (0W) and 2 (2W) and 4 (4W) weeks after ICS withdrawal.

Results: EVI was higher in controls than in patients, and significant within-patient reduction occurred at 4W as compared to 2W or 0W. Area under curve of the ROC curve (controls vs all patients) at 4W was 0.78 (95% CI 0.70-0.85). Children who were administered bronchodilator by parental decision had lower EVI than those without bronchodilator need at 4W, but not at 0W or 2W. Patients with parent-reported airway infection, but no bronchodilator need, had normal EVI. Measurement success rate was 94%.

Conclusion: EVI was lower in patients than in controls and it reduced further after controller medication withdrawal, especially in the presence of parentally perceived wheeze symptoms. This technique shows a significant potential for routine lung function testing of wheezy young children.

Keywords: asthma; home monitoring; lung function; obstruction; paediatric; tidal breathing; wheeze.

Conflict of interest statement

VPS and JV hold patents relating to impedance pneumography. VPS and AH are employees of Revenio Group Corporation that commercialises impedance pneumography technology. JK reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, Orion Pharma and Teva outside the submitted work. MP, JK and JGT have no conflict of interest to disclose.

© 2020 The Authors. Pediatric Allergy and Immunology published by John Wiley & Sons Ltd.

Figures

Figure 1

Sketch of the impedance pneumography (IP) measurement set‐up

Figure 2

Measured expiratory variability index (EVI) values in controls and patients at different time points. P values shown only for within‐patient changes. The rectangle covers 25th‐75th percentile range and the whiskers extend to extremes, excluding outliers, defined as being farther than 1.5 times IQR from the closer quartile. The line in the middle denotes median

Figure 3

Discriminative capacity of expiratory variability index (EVI) presented by ROC curve between controls (115 measurements) and all patients and patients with (BD+) or without (BD−) bronchodilator use at 4W time point

Figure 4

Expiratory variability index (EVI) values with respect to limits of normal, study time points (0W, 2W, 4W) and bronchodilator (BD) use. BD+ and BD− indicate bronchodilator was or was not used, respectively, during the EVI measurement day or night. Numbers within the bars refer to the number of patients in each category. Panel A shows the EVI values presented with respect to the 5th and 10th percentiles of the EVI values of the controls (12.0 and 14.0, respectively). Panel B shows the EVI change from 0W to 4W presented with respect to the 5th and 95th percentiles of the changes in the controls (−3.3 and +3.3, respectively)